Sagent Turns Generic Injectable Shortages Into Business Opportunity
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty generic manufacturer has a facility dedicated to producing shortage drugs, a seemingly endless commercial opportunity given the development, regulatory and reimbursement challenges in the sterile injectable space.
You may also be interested in...
Cheap Drugs Create Quality Temptations, FDA Official Says
FDA will focus on enforcing quality standards, but remains aware of its indirect influence on pricing.
Cheap Drugs Create Quality Temptations, FDA Official Says
FDA will focus on enforcing quality standards, but remains aware of its indirect influence on pricing.
Deal Watch: Tax Policy Changes Claiming Victims Already, As Salix/Cosmo Plans Abandoned
Abandoned deals were the order of the week as the Salix/Cosmo breakup followed Novartis’ exit from hepatitis C drug development and a partnership in that space with Enanta. J&J, however, increased its bet on HCV by acquiring Alios, one of several noteworthy buyouts occurring during the week.